Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial.

The reductions from baseline in total spine bone erosion score were numerically greater for the pooled tofacitinib group and both individual tofacitinib doses versus placebo, although differences did not reach statistical significance (LS mean pooled tofacitinib versus placebo: − 0.09 vs. − 0.04, p = 0.3683) (Table 2 ).

also in 111,027 other papers